AK117
AK117 is an experimental investigational agent whose form is not stated in the registry from Akeso in phase 3 trials for head and neck squamous cell carcinoma, colorectal cancer and non-small-cell lung cancer, with its target not yet stated publicly.
Overview
AK117 is an investigational agent whose form is not stated in the registry developed by Akeso. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: AK117 via intravenous (IV) infusion until disease progression or unacceptable toxicity. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06601335 (A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)), in head and neck squamous cell carcinoma, colorectal cancer, non-small-cell lung cancer, acute myeloid leukaemia and triple-negative breast cancer. The largest, NCT06601335, plans to enrol 510 participants with primary completion expected 2027-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"AK117" OR ABSTRACT:"AK117") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AK117, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentAK119
Shares Akeso, Colorectal cancer and the tags pipeline, ctgov-ingest.
- TreatmentOleclumab
Shares Triple-negative breast cancer (TNBC), Colorectal cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentJK08
Shares Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC), Colorectal cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentPM8002
Shares Small-cell lung cancer, Triple-negative breast cancer (TNBC), Colorectal cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentMCLA-129
Shares Head and neck squamous cell carcinoma, Colorectal cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentJYP0015
Shares Colorectal cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentAL8326
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.
- TreatmentVS-7375
Shares Colorectal cancer, Non-small-cell lung cancer and the tags pipeline, ctgov-ingest.